In the News
Molecular Dx Company Biocartis ‘At Inflection Point’ As It Eyes Infectious Disease Market
Executive Summary Belgian developer of cancer diagnostics is building an infectious disease portfolio on the back of its new SARS-CoV-2 test and collaborations with Immunexpress and Endpoint Health.
SCCM Podcast: Severe COVID-19 and Sepsis
Severe COVID-19 infection can be a form of viral sepsis with occasionally concomitant bacterial infection. Pamela M. Peeke MD, MPH, FACP, FACSM, is joined by Russell Miller, MD, MPH, FCCM, to discuss the definition of sepsis and overlap with case descriptions of patients with severe COVID-19, how experience with viral...
Biocartis announces market release of SeptiCyte RAPID test on Idylla
Biocartis Group has released of SeptiCyte RAPID on Idylla as a CE-marked IVD test. SeptiCyte RAPID is a host-response test that distinguishes sepsis from non-infectious systemic inflammation in patients suspected of sepsis and provides actionable results in about one hour.
Q&A: Sepsis detection technology that can triage COVID-19 patients
Ian Bolland caught up with Dr. Rolland Carlson, CEO of Immunexpress, to talk about a molecular diagnostic, SeptiCyte RAPID, which is used to detect sepsis and offers the potential to triage severe COVID-19 patients in the emergency department. Expand Briefly, tell us more about Immunexpress – how did the idea...
Immunexpress, Biocartis to Roll Out Sepsis Test in Europe Ahead of Planned US Launch
Immunexpress and its partner Biocartis plan to introduce a new, rapid test for sepsis in Europe this quarter ahead of a potential US Food and Drug Administration 510(k) clearance for the assay later this year. The companies are positioning the test, called SeptiCyte Rapid, to triage COVID-19 patients who could...
Immunexpress – Near-Patient Diagnostic For Sepsis – SeptiCyte® RAPID
Dr. Rollie Carlson, CEO of Immunexpress discusses the development and commercialization plans for SeptiCyte® RAPID. SeptiCyte® RAPID is a test that quantifies the immune response to infection and will provide actionable results in about one hour to guide physicians when making patient management decisions.
Conquering Sepsis Clinical Trial Design
Designing and operating clinical trials for diagnosing sepsis can be a challenge, as the gold standard for sepsis detection offers a very low prediction rate due to the nature of how sepsis evolves in patients. FDA gold-standard septic blood cultures predict sepsis only 14% of the time, which makes it...
Biocartis Group partners with Immunexpress
For co-commercialisation agreement for SeptiCyte RAPID Test for use on Biocartis’ fully automated molecular diagnostics platform Idylla Biocartis Group recently announced the expansion of its partnership with Immunexpress with a co-commercialisation agreement for the SeptiCyte RAPID Test for use on Biocartis’ fully automated molecular diagnostics platform Idylla. The SeptiCyte RAPID...
Biocartis, Immunexpress Ink Co-Commercialization Agreement for Sepsis Test
Biocartis has expanded its current partnership with Seattle-based Immunexpress by launching a co-commercialization agreement for Immunexpress' SeptiCyte Rapid test on Biocartis' Idylla platform. As part of the expanded collaboration, Biocartis will lead commercialization in Europe as the exclusive distributor of the SeptiCyte Rapid test, while Immunexpress will lead commercialization of the test in the...
Q&A: BARDA Director Rick Bright Discusses New Programs, Focus on Diagnostics
Rick Bright joined the Biomedical Advanced Research and Development Authority in 2010 following a scientific career addressing influenza at the US Centers for Disease Control and Prevention and at PATH, plus a stint in industry at a vaccine development firm. Now a 12-year-old agency, BARDA was always intended to be...
Execs On The Move: Marketing And Sales Appointments At Quest, SomaLogic And Immunexpress
Quest Diagnostics and SomaLogic, a protein biomarker discovery and diagnostics company, will each bring on a new chief commercial officer; Immunexpress, a sepsis diagnostics firm, hired a VP for market development and commercial operations; and more.
Surviving sepsis: Beth’s story
There are some unspoken rules in the TV news business, like always assume the microphone is hot and stay out of other photographers’ shots. Another is to keep the story succinct. Even on a one-hour broadcast, a general report may last a minute and a half, possibly two. But there...